Abstract
At present, in vivo allergy diagnosis and allergen-specific immunotherapy (AIT) are still based on allergens extracted from natural material. The inherent content and activity change of allergen source cannot be resolved, which impedes the standardization of AIT and limits doctors’ desire to recommend it. With the increasing use of allergen molecules in allergy diagnosis, the molecular allergens in AIT are believed to be the future trend. However, the current clinical phase III trials are not satisfying. Improvements have been made in the field of allergen extracts or molecular allergens—namely extraction methods, adjuvants, recombinant allergen fragments, and personalized medicine. In this article, we review recent progress in allergens preparation for AIT, the needs for further development and possible technical solutions available through molecular allergology.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
